Cagrilintide side effects are real but manageable — most are GI-related, peak during dose escalation, and improve over time. If you're considering this amylin analog through TelosRX, here's exactly what Phase 3 clinical trials show.
Cagrilintide sits in a different pharmacological class than GLP-1 agonists. It mimics amylin — a hormone your pancreas releases alongside insulin. That distinction matters, because the side effects are related but not identical to what you'd see with semaglutide or tirzepatide.
Our clinical team fields these questions regularly. Here are the most common ones, answered with Phase 3 trial data.
Q1: What Is Cagrilintide, and Why Does It Cause Side Effects?
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Natural amylin breaks down within minutes; cagrilintide is engineered to last roughly one week per injection. It works by binding amylin and calcitonin receptors in the brain — slowing gastric emptying and reducing appetite.
The side effects flow directly from that mechanism. Slowing gastric emptying is how the compound reduces hunger. But that same effect can cause nausea, fullness that tips into discomfort, and constipation. The brain signaling that suppresses appetite sometimes overshoots into outright nausea before the body adjusts.
Unlike GLP-1 agonists, cagrilintide doesn't directly stimulate insulin secretion. That means lower standalone hypoglycemia risk — but its amylin signaling brings a distinct GI profile.
Q2: What Are the Most Common Cagrilintide Side Effects?
The Phase 3 REDEFINE trial program provides the clearest dataset. Across monotherapy arms, GI effects dominated the adverse event list — especially during the 20-week dose-escalation phase.
| Side Effect | Reported Frequency | Typical Onset | When It Eases |
|---|---|---|---|
| Nausea | 33–40% | First weeks of dosing | After maintenance dose (~week 16+) |
| Constipation | ~15–20% | Early-to-mid escalation | Ongoing; manageable with hydration |
| Vomiting | ~10–12% | First weeks | Typically improves within weeks |
| Injection site reaction | ~8–10% | Immediately post-injection | Resolves within 24–48 hours |
| Fatigue | ~5–8% | First weeks | Generally self-limiting |
| Excess appetite suppression | Variable | Ongoing | Intended effect; monitor caloric intake |
Most adverse events were mild to moderate in severity. Rates of serious GI events requiring discontinuation were low in monotherapy trials — comparable to other weight-management peptides in this class.
A 2025 systematic review and meta-analysis found cagrilintide's overall GI adverse event rate broadly comparable to GLP-1 agonists, though the vomiting rate was notably lower — roughly one-third the rate observed with semaglutide at comparable doses.
Q3: How Do Cagrilintide Side Effects Compare to Semaglutide?
The two compounds hit overlapping biological targets through different mechanisms, so their side effect profiles differ in clinically meaningful ways.
Semaglutide activates GLP-1 receptors throughout the gut and brain — nausea and vomiting are its most common GI complaints. Cagrilintide acts on amylin and calcitonin receptors, slowing gastric emptying more selectively. The result: similar nausea rates but markedly lower vomiting with cagrilintide alone.
The key caveat is combination use. When cagrilintide combines with semaglutide — the CagriSema formulation in REDEFINE trials — nausea reached ~57% of participants versus ~33–40% for monotherapy. For semaglutide's own detailed profile, see our guide: Compounded Semaglutide via Telehealth: A 2026 Patient Guide.
Q4: How Long Do Cagrilintide Side Effects Typically Last?
Timing depends heavily on where you are in the titration schedule. Cagrilintide follows a slow escalation — starting at 0.16 mg per week, reaching the 2.4 mg maintenance dose around week 16–20.
Most GI side effects peak in weeks 1–8 and improve significantly once the body adapts to sustained amylin signaling. By maintenance dosing, the majority of REDEFINE participants reported either resolution or substantial improvement in GI symptoms.
Injection site reactions are typically short-lived — 24 to 48 hours per injection. Rotating sites between the abdomen, thighs, and upper arms reduces local reaction frequency.
Q5: Are There Serious Cagrilintide Side Effects to Watch For?
Serious adverse events were uncommon in Phase 3 data, but these warrant attention:
- Hypoglycemia: Low risk when used alone. Risk increases significantly if combined with insulin or insulin secretagogues. Anyone on diabetes medications needs careful monitoring and provider oversight.
- Pancreatitis: A theoretical class concern shared with amylin analogs. No specific signal emerged from cagrilintide trials, but report any severe, persistent abdominal pain to your provider immediately.
- Gallbladder issues: Rapid weight loss from any effective compound increases gallstone risk. This is a secondary effect of efficacy, not direct pharmacology.
- Persistent vomiting: If vomiting prevents adequate nutrition and hydration, dose adjustment or a temporary hold may be needed. That's a clinical decision — not something to manage independently.
All TelosRX protocols are subject to medical approval by a licensed provider who evaluates your individual history before and during any compounded peptide protocol. Ready to discuss your specific situation? Read our REDEFINE trial breakdown, then start your evaluation.
Q6: How Can You Manage Cagrilintide Side Effects?
The slow dose-escalation schedule is itself the primary management strategy. Additional approaches that help:
- Smaller, more frequent meals: Reduces GI discomfort during early escalation when gastric emptying is slowest.
- Consistent hydration: Constipation risk increases if fluid intake drops — especially when appetite suppression reduces overall food and water intake.
- Rotate injection sites: Systematic rotation between abdomen, thighs, and upper arms minimizes local reactions.
- Asynchronous provider communication: TelosRX operates as an asynchronous telehealth service. If side effects feel severe or persist, update your provider through the portal. Dose holds and adjustments are standard clinical tools.
For a broader comparison of GLP-1 tolerability, see our tirzepatide vs semaglutide comparison. Ready to explore whether cagrilintide-based therapy fits your situation? Submit your intake at TelosRX — no phone call required.
Q7: Is Cagrilintide FDA-Approved? What Does That Mean for Access?
Cagrilintide is not FDA-approved as a standalone compound as of mid-2026. It remains under Phase 3 investigation through the REDEFINE trial program. Novo Nordisk submitted CagriSema — the cagrilintide plus semaglutide combination — for FDA review in late 2025. If approved, that would cover the combination product, not compounded cagrilintide alone.
Compounded cagrilintide is prepared under federal compounding regulations and is not equivalent to an FDA-approved product. Access requires a licensed provider to evaluate your medical history and determine appropriateness — approval is not guaranteed. The REDEFINE trial program on ClinicalTrials.gov continues to generate the evidence base that will inform future prescribing and regulatory decisions.
Frequently Asked Questions
Does cagrilintide cause hair loss?
Hair shedding — clinically called telogen effluvium — is associated with significant caloric restriction and rapid weight loss from any effective weight-loss protocol, not with cagrilintide pharmacology specifically. No direct signal for drug-induced hair loss was identified in Phase 3 trials. Adequate protein intake during a caloric deficit helps reduce this risk.
Can cagrilintide cause thyroid problems?
Cagrilintide signals via calcitonin receptors expressed in thyroid tissue. Phase 3 trials did not identify a thyroid cancer signal. Individuals with a personal or family history of thyroid cancer should discuss this with their provider before starting any amylin or calcitonin receptor-targeting analog.
Is cagrilintide safe for people with Type 2 diabetes?
Phase 3 trials included participants with Type 2 diabetes. Cagrilintide demonstrated a favorable glycemic effect without causing hypoglycemia when used alone. Risk increases meaningfully if you're already on insulin or sulfonylureas. Your provider reviews your full medication list as part of the evaluation — this is not something to self-assess.
What happens if you miss a cagrilintide dose?
Missing one weekly dose is generally not clinically significant. Standard guidance for weekly injectables: administer the missed dose as soon as you remember if it's within a few days, then resume your normal schedule. If the next scheduled dose is imminent, skip the missed one and continue. Your licensed provider's protocol includes specific guidance.
Are cagrilintide side effects worse at higher doses?
Yes — GI side effects are dose-dependent. The 2.4 mg maintenance dose produces more frequent nausea than the 0.16 mg starting dose. The protocol escalates slowly over 16–20 weeks specifically to allow the body to adapt, which is why early side effects often reduce substantially by maintenance dosing.
Can I take anti-nausea medication while on cagrilintide?
This is a clinical question that requires provider input. Some anti-emetics are commonly used during dose escalation with peptide weight-loss compounds. Flag GI severity to your licensed provider through your TelosRX portal and let them guide the appropriate response — do not self-prescribe.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.